Safety and Efficacy Study of MT-2990 in Women With Endometriosis

Mitsubishi Tanabe Pharma

Status and phase: Completed; Phase 2

Conditions: Endometrial Related Pain

Treatments: Drug: Placebo; Drug: MT-2990

Study type: Interventional

Funder types: Industry

Identifiers

NCT03840993

MT-2990-A01

Details and patient eligibility

About

The purpose of this study is to assess the safety and efficacy of MT-2990 for treatment of moderate to severe endometriosis-related pain in women with surgically diagnosed endometriosis.

Enrollment: 76 patients

Sex: Female

Ages: 18 to 49 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provide written informed consent to participate in this study
• Agree to approximately 30-90 day washout interval of hormonal therapies, if applicable
• Have a history of regular menstrual cycles
• Have a body mass index < 45 kg/m^2 (inclusive)
• Have documented surgical/laparoscopy diagnosis of endometriosis with 10 years
• Agree to use 2 forms of nonhormonal contraception throughout the study
• In the Investigator's opinion, subject is able to understand the nature of the study and any risk involved in participation, and is willing to cooperate and comply with the protocol restrictions and requirements including transvaginal ultrasound.
• Have moderate to severe endometrial related pain

Exclusion criteria

• Subject is pregnant, breast feeding, or planning a pregnancy.
• Subject is < 6 months postpartum, postabortion, or post-pregnancy.
• Willing to remove a hormonal intrauterine device (IUD) at least 30 days prior to screening. (Non hormonal IUDs do not have to be removed)
• Aspartate aminotransferase (AST), alanine aminotransferase (ALT) , or total bilirubin ≥ 2.0 × upper limit of normal (ULN) above the reference range
• Have immunosuppression due to underlying medical condition
• Corrected QT interval using Fridericia's formula (QTcF) or Corrected QT interval using Bazett's formula (QTcB) ≥ 450 msec or clinically important abnormal findings on the ECG
• Subject is not up-to-date on breast screening according to current guidelines.
• Has a surgical history of hysterectomy, bilateral oophorectomy and any other recent major surgery
• Subject is required more than 2 weeks of continuous use of prohibited long-acting narcotic or immediate release narcotic for treatment of endometriosis-associated pain.
• Have chronic pelvic pain for nonendometriosis related causes, which require systemic pharmaceutical chronic therapy for pain
• Have other chronic pain syndrome which require chronic analgesic or other chronic therapy
• Have a clinically significant gynecologic condition identified on the transvaginal ultrasound (TVU) (e.g., complex ovarian cyst > 3 cm or simple ovarian cyst > 5 cm, clinically significant endometrial pathology, single fibroid ≥ 4 cm or multiple (> 4) fibroids that measure ≥ 2 cm or symptomatic submucosal fibroid of any size
• Have a current history of undiagnosed abnormal genital bleeding

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

76 participants in 2 patient groups, including a placebo group

MT-2990

Experimental group

Description:

MT-2990, over 16 weeks

Treatment:

Drug: MT-2990

Placebo

Placebo Comparator group

Description:

Placebo, over 16 weeks

Treatment:

Drug: Placebo